Maspin expression in epithelial ovarian cancer and associations with poor prognosis: A Gynecologic Oncology Group study

Poor Prognosis ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression

The regulation of MASPIN expression in epithelial ovarian cancer: Association with p53 status, and MASPIN promoter methylation: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.08.003 ◽

2011 ◽

Vol 123 (2) ◽

pp. 314-319 ◽

Cited By ~ 9

Author(s):

Angeles Alvarez Secord ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Zhiqing Huang ◽

Paula S. Lee ◽

...

Keyword(s):

Ovarian Cancer ◽

Promoter Methylation ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Maspin Expression ◽

P53 Status

An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2004.05.033 ◽

2004 ◽

Vol 94 (2) ◽

pp. 368-374 ◽

Cited By ~ 40

Author(s):

David H Moore ◽

James T Kauderer ◽

Jeffrey Bell ◽

John P Curtin ◽

Linda Van Le

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽

Alternative Treatments ◽

Oncology Group Study ◽

Factors Influencing

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.01.008 ◽

2012 ◽

Vol 125 (2) ◽

pp. 421-426 ◽

Cited By ~ 32

Author(s):

Jennifer M. Rubatt ◽

Kathleen M. Darcy ◽

Chunqiao Tian ◽

Franco Muggia ◽

Rajiv Dhir ◽

...

Keyword(s):

Ovarian Cancer ◽

Clinical Outcomes ◽

Gynecologic Oncology ◽

Advanced Stage ◽

Oncology Group ◽

Oncology Group Study ◽

Pre Treatment ◽

Tumor Expression

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.057 ◽

2012 ◽

Vol 125 ◽

pp. S24-S25 ◽

Cited By ~ 3

Author(s):

L. Landrum ◽

J. Java ◽

C. Mathews ◽

G. Lanneau ◽

L. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.11.013 ◽

2021 ◽

Author(s):

Nefertiti C. duPont ◽

Danielle Enserro ◽

Mark F. Brady ◽

Katherine Moxley ◽

Joan L. Walker ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Advanced Stage ◽

Oncology Group ◽

Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.03.021 ◽

2007 ◽

Vol 106 (1) ◽

pp. 221-232 ◽

Cited By ~ 32

Author(s):

Angeles Alvarez Secord ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Epithelial Ovarian Cancer

Oncology Group ◽

Oncology Group Study ◽

Angiogenic Markers ◽

The prognostic significance of pre-operative vs. prechemotherapy CA-125 in high-risk early-stage epithelial ovarian cancer: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.020 ◽

2010 ◽

Vol 116 (3) ◽

pp. 596

Author(s):

J. Chan ◽

T. Chunqiao ◽

K. Yang ◽

J. Kesterson ◽

B. Monk ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Early Stage ◽

Gynecologic Oncology ◽

Prognostic Significance ◽

Ca 125 ◽

Oncology Group ◽

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.073 ◽

2010 ◽

Vol 116 (3) ◽

pp. 301-306 ◽

Cited By ~ 75

Author(s):

John K. Chan ◽

Chunqiao Tian ◽

Gini F. Fleming ◽

Bradley J. Monk ◽

Thomas J. Herzog ◽

...

Keyword(s):

Ovarian Cancer ◽

High Risk ◽

Potential Benefit ◽

Early Stage ◽

Gynecologic Oncology ◽

Exploratory Analysis ◽

Oncology Group ◽

A Phase II Trial of Didemnin B (NSC #335319) in Patients with Previously Treated Epithelial Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199302000-00012 ◽

1993 ◽

Vol 16 (1) ◽

pp. 47-49 ◽

Cited By ~ 18

Author(s):

John H. Malfetano ◽

John A. Blessing ◽

Allan J. Jacobs

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Didemnin B ◽

Oncology Group ◽

Oncology Group Study ◽

Previously Treated

Association between the N-terminally truncated (ΔN) p63α (ΔNp63α) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.035 ◽

2009 ◽

Vol 115 (3) ◽

pp. 424-429 ◽

Cited By ~ 3

Author(s):

Elizabeth L. Jewell ◽

Kathleen M. Darcy ◽

Alan Hutson ◽

Paula S. Lee ◽

Laura J. Havrilesky ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Progression Free Survival ◽

Advanced Stage ◽

Oncology Group ◽

Vegf Expression ◽

Free Survival ◽